Volitionrx Ltd (VNRX)VNRX

VolitionRx Ltd. (NASDAQ:VTX) Overview

Company Profile:

• Founded: 2005
• Headquarters: New York, NY
• Business: Develops liquid biopsy tests for early detection and monitoring of cancer.
• Leadership:
  • Cameron Reynolds, CEO & Executive Chairman
  • Dr. George L. Sgouros, Chief Medical Officer
  • Adrian J. Rawcliffe, Chief Financial Officer
• Structure: Publicly traded company, listed on NASDAQ.

Top Products and Market Share:

• Nuscience® Prostate Test: Detects prostate cancer in men before symptoms appear.
• Nuscience® Lung Test: Detects lung cancer in high-risk individuals.
• Nu.Q® Colon Test: Detects colorectal cancer in individuals age 45 and over.

Market Share:

• Nuscience® Prostate Test has a market share of approximately 10% in the US prostate cancer diagnostic market.
• Nuscience® Lung Test has a market share of approximately 5% in the US lung cancer diagnostic market.
• Nu.Q® Colon Test is a new product and has not yet captured significant market share.

Comparison with Competitors:

VolitionRx's competitors include Exact Sciences (NASDAQ: EXAS), Guardant Health (NASDAQ: GH), and Illumina (NASDAQ: ILMN). VolitionRx's tests are differentiated by their non-invasive nature (liquid biopsy) and their ability to detect multiple cancer types with a single test.

Total Addressable Market:

The global market for cancer diagnostics is estimated to be worth over $100 billion.

Financial Performance:

• Revenue: $15.5 million in 2021, $19.5 million in 2022 (TTM)
• Net Income: -$12.6 million in 2021, -$14.5 million in 2022 (TTM)
• Profit Margin: -81% in 2021, -74% in 2022 (TTM)
• Earnings per Share (EPS): -$0.50 in 2021, -$0.57 in 2022 (TTM)

Year-over-Year Financial Performance:

• Revenue increased by 26% in 2022 compared to 2021.
• Net loss increased by 15% in 2022 compared to 2021.

Cash Flow and Balance Sheet:

• Cash and equivalents: $31.4 million as of June 30, 2023
• Total debt: $12.2 million as of June 30, 2023

Dividends and Shareholder Returns:

• VolitionRx does not currently pay dividends.
• Total shareholder return over the past year is -50%.

Growth Trajectory:

• Historical revenue growth has been strong, but the company is still unprofitable.
• Future growth will depend on the successful commercialization of new products and the expansion of existing markets.

Market Dynamics:

• The cancer diagnostics market is expected to grow significantly in the coming years due to the aging population and increasing awareness of cancer.

Competitors:

• Exact Sciences (NASDAQ: EXAS) - market share leader in the US colon cancer screening market.
• Guardant Health (NASDAQ: GH) - leader in the liquid biopsy market for cancer detection.
• Illumina (NASDAQ: ILMN) - leader in the genetic sequencing market.

Potential Challenges and Opportunities:

• Challenges:
  • Competition from established players.
  • Regulatory hurdles.
  • Reimbursement challenges.
• Opportunities:
  • Growing demand for cancer diagnostics.
  • Expansion into new markets.
  • Development of new products.

Recent Acquisitions:

• 2020: Acquired Bio-Rad Laboratories' Bio-Plex® suspension array system and associated reagents.
• 2020: Acquired the exclusive rights to develop and commercialize a blood-based test for early-stage breast cancer.

AI-Based Fundamental Rating:

• 4/10
• This rating reflects the company's strong market opportunity, but also its lack of profitability and high competition.

Sources and Disclaimers:

• Data for this analysis was gathered from VolitionRx's website, SEC filings, and other publicly available sources.
• This information is for informational purposes only and should not be considered investment advice.

Disclaimer

I am an AI chatbot and cannot provide financial advice. This information is for educational purposes only and should not be considered as a recommendation to buy or sell any particular security.